{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T04:48:47Z","timestamp":1782190127456,"version":"3.54.5"},"reference-count":33,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007128","name":"Natural Science Foundation of Shaanxi Province","doi-asserted-by":"publisher","award":["2024JC-YBMS-740"],"award-info":[{"award-number":["2024JC-YBMS-740"]}],"id":[{"id":"10.13039\/501100007128","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathogens"],"abstract":"<jats:p>Acinetobacter baumannii is a significant pathogen of hospital-acquired infections, and its multidrug resistance (MDR) and extended drug resistance (XDR) have become increasingly severe, posing a global public health challenge. This article provides a narrative review of the major resistance mechanisms of Acinetobacter baumannii, including \u03b2-lactamase production, efflux pump overexpression, target site modification, reduced membrane permeability, and biofilm formation. Additionally, it summarizes the current main drugs and their target sites for treating MDR Acinetobacter baumannii infections, with a focus on the mechanism of action, antibacterial activity, and clinical research progress of the novel fully synthetic fluorocycline antibiotic\u2014eravacycline. Eravacycline inhibits protein synthesis by high-affinity binding to the bacterial ribosomal 30S subunit and demonstrates activity against multidrug-resistant Acinetobacter baumannii (excluding Pseudomonas aeruginosa), providing a potential novel therapeutic option for MDR\/XDR Acinetobacter baumannii infections. Finally, the article outlines future research directions and treatment strategies. Due to the narrative nature of this review, no systematic methodology (e.g., PRISMA) was applied, and the available clinical evidence, particularly for CRAB infections, remains limited.<\/jats:p>","DOI":"10.3390\/pathogens15060642","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T03:27:21Z","timestamp":1781666841000},"page":"642","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Rise in Carbapenem-Resistant Acinetobacter baumannii and the Emergence of Eravacycline as a Treatment Strategy: A Narrative Review"],"prefix":"10.3390","volume":"15","author":[{"given":"Bo","family":"Guan","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The Second Affiliated Hospital of Air Force Medical University, Xi\u2019an 710038, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Honghui Hospital, Xi\u2019an Jiaotong University, Xi\u2019an 710054, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunling","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Honghui Hospital, Xi\u2019an Jiaotong University, Xi\u2019an 710054, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2789-6367","authenticated-orcid":false,"given":"Jing","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Honghui Hospital, Xi\u2019an Jiaotong University, Xi\u2019an 710054, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"dlaf134","DOI":"10.1093\/jacamr\/dlaf134","article-title":"The global epidemiology of carbapenem-resistant Acinetobacter baumannii","volume":"7","author":"Boutzoukas","year":"2025","journal-title":"JAC-Antimicrob. Resist."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Szemraj, M., Piechota, M., Olszowiec, K., Wicha, J., Pruss, A., Sienkiewicz, M., Witeska, M., Szweda, P., and Kot, B. (2025). High Prevalence of Virulence and blaOXA Genes Encoding Carbapenemases Among Acinetobacter baumannii Isolates from Hospitalised Patients in Three Regions of Poland. Pathogens, 14.","DOI":"10.3390\/pathogens14080731"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/lt.24389","article-title":"Carbapenem-resistant Acinetobacter baumannii acquired before liver transplantation: Impact on recipient outcomes","volume":"22","author":"Freire","year":"2016","journal-title":"Liver Transpl."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e14956","DOI":"10.1111\/ctr.14956","article-title":"Incidence, mortality, and risk factors associated with carbapenem-resistant Acinetobacter baumannii bacteremia within 30 days after liver transplantation","volume":"37","author":"Min","year":"2023","journal-title":"Clin. Transpl."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Kyriakidis, I., Vasileiou, E., Pana, Z.D., and Tragiannidis, A. (2021). Acinetobacter baumannii Antibiotic Resistance Mechanisms. Pathogens, 10.","DOI":"10.3390\/pathogens10030373"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2147\/IDR.S228089","article-title":"Acinetobacter baumannii Efflux Pumps and Antibiotic Resistance","volume":"13","author":"Abdi","year":"2020","journal-title":"Infect. Drug Resist."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Vrancianu, C.O., Gheorghe, I., Czobor, I.B., and Chifiriuc, M.C. (2020). Antibiotic Resistance Profiles, Molecular Mechanisms and Innovative Treatment Strategies of Acinetobacter baumannii. Microorganisms, 8.","DOI":"10.3390\/microorganisms8060935"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.jinf.2020.10.016","article-title":"Developing new therapeutic approaches for treating infections caused by multi-drug resistant Acinetobacter baumannii: Acinetobacter baumannii therapeutics","volume":"81","author":"Gallagher","year":"2020","journal-title":"J. Infect."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1515\/hsz-2013-0292","article-title":"Tetracycline antibiotics and resistance mechanisms","volume":"395","author":"Nguyen","year":"2014","journal-title":"Biol. Chem."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40265-016-0545-8","article-title":"Review of eravacycline, a novel fluorocycline antibacterial agent","volume":"76","author":"Zhanel","year":"2016","journal-title":"Drugs"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1177\/1060028019850173","article-title":"Eravacycline: The tetracyclines strike back","volume":"53","author":"Heaney","year":"2019","journal-title":"Ann. Pharmacother."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s40265-019-01067-3","article-title":"Eravacycline: A Review in Complicated Intra-Abdominal Infections","volume":"79","author":"Scott","year":"2019","journal-title":"Drugs"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/phar.2366","article-title":"Evaluation of eravacycline: A novel fluorocycline","volume":"40","author":"Alosaimy","year":"2020","journal-title":"Pharmacotherapy"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"866","DOI":"10.3390\/jcm8060866","article-title":"The efficacy and safety of eravacycline in the treatment of complicated intra-abdominal infections: A systemic review and meta-analysis of randomized controlled trials","volume":"8","author":"Lan","year":"2019","journal-title":"J. Clin. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jgar.2021.10.020","article-title":"A retrospective, multicentre evaluation of eravacycline utilisation in community and academic hospitals","volume":"29","author":"Hobbs","year":"2022","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e0047922","DOI":"10.1128\/spectrum.00479-22","article-title":"Clinical outcomes of eravacycline in patients treated predominately for Carbapenem-resistant Acinetobacter baumannii","volume":"10","author":"Alosaimy","year":"2022","journal-title":"Microbiol. Spectr."},{"key":"ref_17","first-page":"477","article-title":"Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections","volume":"25","author":"Tamma","year":"2024","journal-title":"Clin. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Zhao, C., Wang, X., Zhang, Y., Wang, R., Wang, Q., Li, H., and Wang, H. (2019). In vitro activities of eravacycline against 336 isolates collected from 2012 to 2016 from 11 teaching hospitals in China. BMC Infect. Dis., 19.","DOI":"10.1186\/s12879-019-4093-1"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s10096-023-04616-7","article-title":"In vitro activities of omadacycline, eravacycline, cefiderocol, apramycin and comparator antibiotics against Acinetobacter baumannii causing bloodstream infections in Greece, 2020\u20132021: A multicenter study","volume":"42","author":"Galani","year":"2023","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ijantimicag.2017.06.022","article-title":"Invitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii","volume":"51","author":"Seifert","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1007\/s10096-025-05235-0","article-title":"Eravacycline: Evaluation of susceptibility testing methods and activity against multidrug-resistant Enterobacterales and Acinetobacter","volume":"44","author":"Bogaerts","year":"2025","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis. Off. Publ. Eur. Soc. Clin. Microbiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"34109","DOI":"10.1038\/s41598-025-19642-y","article-title":"In vitro activity of meropenemvaborbactam combinations and eravacycline against carbapenemresistant Acinetobacter baumannii","volume":"15","author":"Abdrabou","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1001\/jamasurg.2016.4237","article-title":"Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the investigating gramnegative infections treated with eravacycline (IGNITE 1) trial: A randomized clinical trial","volume":"152","author":"Solomkin","year":"2017","journal-title":"JAMA Surg."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e0323822","DOI":"10.1128\/spectrum.03238-22","article-title":"In vitro antimicrobial activities of tigecycline, eravacycline, omadacycline and sarecycline against rapidly growing Mycobacteria","volume":"11","author":"Zhang","year":"2023","journal-title":"Microbiol. Spectr."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/cid\/ciy1029","article-title":"IGNITE4: Results of a phase 3, randomized, multicenter, prospective trial of eravacycline vs meropenem in the treatment of complicated intraabdominal infections","volume":"69","author":"Solomkin","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"935343","DOI":"10.3389\/fmed.2022.935343","article-title":"The efficacy and safety of eravacycline compared with current clinically common antibiotics in the treatment of adults with complicated intra-abdominal infections: A Bayesian network meta-analysis","volume":"9","author":"Meng","year":"2022","journal-title":"Front. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"ofad500","DOI":"10.1093\/ofid\/ofad500.1760","article-title":"Real World Experience with Eravacycline for the Treatment of Infections Caused by Carbapenem-Resistant Acinetobacter baumannii","volume":"10","author":"Lim","year":"2023","journal-title":"Open Forum Infect. Dis."},{"key":"ref_28","unstructured":"(2025, June 05). XERAVA\u00ae (Eravacycline) for Injection, for Intravenous Use Initial U.S. Approval: 2018. Available online: https:\/\/xerava-assets.s3.amazonaws.com\/prescribing-information.pdf."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.amjms.2023.09.012","article-title":"Prolonged course of eravacycline leading to acute pancreatitis","volume":"366","author":"Stefanos","year":"2023","journal-title":"Am. J. Med. Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1128\/AAC.06187-11","article-title":"Target- and resistance based mechanistic studies with TP-434, a novel fuorocycline antibiotic","volume":"56","author":"Grossman","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"6989","DOI":"10.1128\/AAC.01646-16","article-title":"Eravacycline is active against bacterial isolates expressing the polymyxin resistance gene mcr-1","volume":"60","author":"Fyfe","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1128\/AAC.04809-14","article-title":"Activity of eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including multidrug-resistant isolates, from New York City","volume":"59","author":"Abdallah","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1093\/ofid\/ofac591","article-title":"Eravacycline Associated Hypofibrinogenemia: A Case Series of Transplant Patients with Mycobacterium Abscessus Infections and Review of Literature","volume":"9","author":"Rausch","year":"2022","journal-title":"Open Forum Infect. Dis."}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/15\/6\/642\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T04:18:45Z","timestamp":1782188325000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/15\/6\/642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":33,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["pathogens15060642"],"URL":"https:\/\/doi.org\/10.3390\/pathogens15060642","relation":{},"ISSN":["2076-0817"],"issn-type":[{"value":"2076-0817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]}}}